Chronic Chagas disease: From basics to laboratory medicine

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 271-294

  Haberland, Annekathrin ^a   Munoz Saravia, Silvia Gilka ^a   Wallukat, Gerd ^b   Ziebig, Reinhard ^a   Schimke, Ingolf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

autoantibodies; cardiac markers; Chagas cardiomyopathy; Chagas disease; inflammation marker; oxidative stress marker

Indexed keywords

AUTOANTIBODY; BENZNIDAZOLE; G PROTEIN COUPLED RECEPTOR; NIFURTIMOX;

ACUTE DISEASE; BLOOD TRANSFUSION; CHAGAS DISEASE; CHRONIC DISEASE; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; LABORATORY DIAGNOSIS; MIGRATION; NEUROLOGIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOURISM; TRYPANOSOMA CRUZI;

CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 84875455911     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0316     Document Type: Review

References (210)

1. WHO Expert Committee. Control of Chagas disease. World Health Organ Tech Rep Ser 2002;905:i-vi, 1-109.
2. Anonymous. Recommendations from a satellite meeting. Mem Inst Oswaldo Cruz 1999;94:429-32.
3. Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 2009;104:1051-4.
4. Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect Dis 2012;54:845-52.
5. Dorn PL, Perniciaro L, Yabsley MJ, Roellig DM, Balsamo G, Diaz J, et al. Autochthonous transmission of Trypanosoma cruzi, Louisiana. Emerg Infect Dis 2007;13:605-7.
6. Dias JC, Prata A, Correia D. Problems and perspectives for Chagas disease control: in search of realistic analysis. Rev Soc Bras Med Trop 2008;41:193-6.
7. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 2009;49:e52-4.
8. Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 2010;115:14-21.
9. Guerri-Guttenberg RA, Grana DR, Ambrosio G, Milei J. Chagas cardiomyopathy: Europe is not spared! Eur Heart J 2008;29:2587-91
10. Guerri-Guttenberg RA, Ciannameo A, Di Girolamo C, Milei JJ. Chagas disease: an emerging public health problem in Italy? Infez Med 2009;17:5-13.
11. Sociétéde pathologie exotique. Chagas disease. American trypanosomiasis. Recommendation for non-endemic zones. Med Trop (Mars) 2010;70:131-2.
12. Perez-Molina JA, Perez-Ayala A, Parola P, Jackson Y, Odolini S, Lopez-Velez R. EuroTravNet: imported Chagas disease in nine European countries, 2008 to 2009. Euro Surveill 2011; 16.pii:19966.
13. Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill 2011;16.pii:19968.
14. Dias JC, Schofield CJ, Machado EM, Fernandes AJ. Ticks, ivermectin, and experimental Chagas disease. Mem Inst Oswldo Cruz 2005;100:829-32.
15. Yacoub S, Kotit S, Yacoub MH. Disease appearance and evolution against a background of climate change and reduced resources. Philos Transact A Math Phys Eng Sci 2011;369: 1719-29.
16. Oliveira I, Torrico F, Muñoz J, Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev Anti Infect Ther 2010;8:945-56.
17. Riera C, Guarro A, Kassab HE, Jorba JM, Castro M, Angrill R, et al. Congenital transmission of Trypanosoma cruzi in Europe (Spain): a case report. Am J Trop Med Hyg 2006;75:1078-81.
18. Flores-Chavez MD, Merino FJ, Garcia-Bujalance S, Martin-Rabadan P, Merino P, Garcia-Bermejo I, et al. Surveillance of Chagas disease in pregnant women in Madrid, Spain, from 2008 to 2010. Euro Surveill 2011;16.pii:19974.
19. Basile L, Oliveira I, Ciruela P, Plasencia A; Working Group for Developing the Catalonian Screening Programme for Congenital Transmission of Chagas Disease. The current screening programme for congenital transmission of Chagas disease in Catalonia Spain. Euro Surveill 2011;16.pii:19972.
20. Jackson Y, Chappuis F. Chagas disease in Switzerland: history and challenges. Euro Surveill 2011;16.pii:19963.
21. Ferreira CS, Martinho PC, Amato Neto V, Cruz RR. Pasteurization of human milk to prevent transmission of Chagas disease. Rev Inst Med Trop Sao Paulo 2001;43:161-2.
22. Chagas'Disease Argentine Collaborative Transplant Consortium, Casadei D. Chagas'disease and solid organ transplantation. Transplant Proc 2010;42:3354-9.
23. Schmunis GA. Risk of Chagas disease through transfusions in the Americans. Medicina (B Aires) 1999;59:125-34.
24. Dias JC, Schofield CJ. The evolution of Chagas disease (American trypanosomiasis) control after 90 years since Carlos Chagas discovery. Men Inst Oswaldo Cruz 1999;94(Suppl 1):103-21.
25. Centers for Disease Control and Prevention (CDC). Blood donor screening for Chagas disease-United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007;56:141-3.
26. Real Decreto 1088/2005 por el que se establecen los requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión del 20 de septiembre 2005, n úm. 225,31288-304.
27. Angheben A, Anselmi M, Gobbi F, Marocco S, Monteiro G, Buonfrate D, et al. Chagas disease in Italy: breaking an epidemiological silence. Euro Surveill 2011;16.pii:19969.
28. Sandahl K, Botero-Kleiven S, Hellgren U. Chagas'disease in Sweden-great need of guidelines for testing. Probably hundreds of seropositive cases, only a few known. Lakartidningen 2011;108:2368-71.
29. Salamanca-Dejour D, Blanchet D, Aznar C, La Ruche G, Jeannel D, Gastellu-Etchegorry M. Chagas disease (American trypanosomiasis) in France. Med Mal Infect 2012;42:344-8.
30. Biolo A, Ribeiro AL, Clausell N. Chagas disease: 100 years after its discovery. A systemic review. Acta Trop 2010;115:5-13.
31. Coura JR, Borges-Pereira J. Chagas disease. Lancet 2010;375:1388-402.
32. Lescure FX, Le Loup G, Freilij H, Develoux M, Paris L, Brutus L, et al. Chagas disease: changes in knowledge and management. Lancet Infect Dis 2010;10:556-70.
33. Teixeira AR, Hecht MM, Guimaro MC, Sousa AO, Nitz N. Pathogenesis of Chagas'disease: parasite persistence and autoimmunity. Clin Microbiol Rev 2011;24:592-630.
34. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402.
35. Gironés N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas'disease. Curr Top Microbiol Immunol 2005;296:89-123.
36. Dutra WO, Gollob KJ. Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis 2008;21:287-92.
37. Sathler-Avelar R, Vitelli-Avelar DM, Teixeira-Carvalho A, Martins-Filho OA. Innate immunity and regulatory T-cells in human Chagas disease: what must be understood? Mem Inst Oswaldo Cruz 2009;104(Suppl1):246-51.
38. de Araújo FF, Vitelli-Avelar DM, Teixeira-Carvalho A, Antas PR, Assis Silva Gomes J, Sathler-Avelar R, et al. Regulatory T cells phenotype in different clinical forms of Chagas'disease. PLoS Negl Trop Dis 2011;5:e992.
39. Moncayo A, Ortiz Yanine MI. An update on Chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 2006;100:663-77.
40. Ochs DE, Hnilica VS, Moser DR, Smith JK, Kirchhoff LV. Postmortem diagnosis of autochthonous acute chagasic myocarditis by polymerase chain reaction amplification of a species-specific DNA sequence of Trypanosoma cruzi. Am J Trop Med Hyg 1996;54:526-9.
41. Martin D, Tarleton R. Generation, specificity, and function of CD8 + T cells in Trypanosoma cruzi infection. Immunol Rev 2004;201:304-17.
42. Matsuda NM, Miller SM, Evora PR. The chronic gastrointestinal manifestations of Chagas disease. Clinics (Sao Paulo) 2009;64:219-24.
43. Pinazo MJ, Cañas E, Elizalde JI, García M, Gascón J, Gimeno F, et al. Diagnosis, management and treatment of chronic Chagas'gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol 2010;33: 191-200.
44. Py M, Pedrosa R, Silveira J, Medeiros A, Andre C. Neurological manifestations in Chagas disease without cardiac dysfunction: correlation between dysfunction of the parasympathetic nervous system and white matter lesions in the brain. J Neuroimaging 2009;19:332-6.
45. Córdova E, Maiolo E, Corti M, Orduña T. Neurological manifestations of. Chagas'disease. Neurol Res 2010;32:238-44.
46. Chuenkova MV, Pereiraperrin M. Neurodegeneration and neuroregeneration in Chagas disease. Adv Parasitol 2011;76:195-233.
47. Andrade LO, Machado CR, Chiari E, Pena SD, Macedo AM. Trypanosoma cruzi: role of host genetic background in the differential tissue distribution of parasite clonal populations. Exp Parasitol 2002;100:269-75.
48. Tibayrenc M. Human genetic diversity and the epidemiology of parasitic and other transmissible diseases. Adv Parasitol 2007;64:377-462.
49. Layrisse Z, Fernandez MT, Montagnani S, Matos M, Balbas O, Herrera F, et al. HLA-C*03 is a risk factor for cardiomyopathy in Chagas disease. Human Immunol 2000;61:925-9.
50. Garcia Borras S, Racca L, Cotorruelo C, Biondi C, Beloscar J, Racca A. Distribution of HLA-DRB1 alleles in Argentinean patients with Chagas'disease cardiomyopathy. Immunol Invest 2009;38:268-75.
51. FaéKC, Drigo SA, Cunha-Neto E, Ianni B, Mady C, Kalil J, et al. HLA and b-myosin heavy chain do not influence susceptibility to Chagas'disease cardiomyopathy. Microbes Infect 2000;2: 745-51.
52. Kirchhoff LV. Chagas disease (American Trypanosomiasis). Available from: http://emedicine.medscape.com/article/214581-overview. Accessed on 24 September 2012.
53. Tafuri WL, Maria TA, Lopes ER, Chapadeiro E. Electron microscopy of the myocardium in human Trypanosomiasis cruzi. Rev Inst Med Trop Sao Paulo 1973;15:347-70.
54. Rossi MA. Connective tissue skeleton in the normal left ventricle and in hypertensive left ventricular hypertrophy and chronic chagasic myocarditis. Med Sci Monit 2001;7:820-32.
55. Oliveira JS. A natural human model of intrinsic heart nervous system denervation: Chagas'cardiopathy. Am Heart J 1985;110:1092-8.
56. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas'disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop Sao Paulo 2000;42:1561-71.
57. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63: 111-8.
58. Hernández-Becerril N, Nava A, Reyes PA, Monteón VM. IgG subclasses reactivity to Trypanosoma cruzi in chronic chagasic patients. Arch Cardiol Mex 2001;71:199-205.
59. Pittella JE. Central nervous system involvement in Chagas disease: a hundred-year-old history. Trans R Soc Trop Med Hyg 2009;103:973-8.
60. Oliveira-Filho J. Stroke and brain atrophy inchronic Chagas disease patients. A new theory proposition. Dement Neuropsychol 2009;3:22-6.
61. Py MO. Neurologic manifestations of Chagas disease. Curr Neurol Neurosci Rep 2011;11:536-42.
62. Engman DM, Leon JS. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop 2002;81:123-32.
63. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med 2008;8:510-8.
64. Cunha-Neto E, Teixeira PC, Nogueira LG, Kalil J. Autoimmunity. Adv Parasitol 2011;76:129-52.
65. Pérez-Molina JA, Rodríguez-Guardado A, Soriano A, Pinazo MJ, Carrilero B, García-Rodríguez M, et al. Guidelines on the treatment of chronic coinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials 2011;12:287-98.
66. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012;25:450-7.
67. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 2006;39:41-54.
68. Reis DD, Gazzinelli RT, Gazzinelli G, Colley DG. Antibodies to Trypanosoma cruzi express idiotypic patterns that can differentiate between patients with asymptomatic or severe Chagas'disease. J Immunol 1993;150:1611-8.
69. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011;7:659-74.
70. Wallukat G, Mu ñoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas'cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas'patients. J Am Coll Cardiol 2010;55:463-8.
71. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009;73:602-7.
72. Dandel M, Wallukat G, Potapov E, Hetzer R. Role of b1-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2012;217:511-20.
73. Zuo L, Bao H, Tian J, Wang X, Zhang S, He Z, et al. Long-term active immunization with a synthetic peptide corresponding to the second extracellular loop of b1-adrenoceptor induces both morphological and functional cardiomyopathic changes in rats. Int J Cardiol 2011;149:89-94.
74. Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, et al. Treatment with benznidazole during the chronic phase of experimental Chagas'disease decreases cardiac alterations. Antimicrob Agents Chemother 2005;49:1521-8.
75. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7:157-63.
76. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc 2011;86:561-83.
77. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, Tran AN, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005;309:409-15.
78. Marian-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas'cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008;156:37-43.
79. Muratore CA, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc Health Risk Manag 2010;6:593-601.
80. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy-where do we stand after a hundred years? Prog Cardiovasc Dis 2010;52:300-16.
81. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 2007;153:544.e1-8.
82. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010;3:82-8.
83. Sousa, Xavier SS, Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas'disease. Arq Bras Cardiol 2008;91:306-10.
84. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas'cardiomyopathy. Circulation 1994;90:3098-102.
85. Bertolino ND, Villafanha DF, Cardinalli-Neto A, Cordeiro JA, Arcanjo MJ, Theodoropoulos TA, et al. Prognostic impact of Chagas'disease in patients awaiting heart transplantation. J Heart Lung Transplant 2010;29:449-53.
86. Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Boccia EA, et al. Risk factors for Chagas'disease reactivation after heart transplantation. J Heart Lung Transplant 2008;27:597-602.
87. Moreira LF, Galantier J, Benício A, Leirner AA, Cestari IA, Stolf NA. Left ventricular circulatory support as bridge to heart transplantation in Chagas'disease cardiomyopathy. Artif Organs 2007;31:253-8.
88. Vilas-Boas F, Feitosa GS, Soares MB, Mota A, Pinho-Filho JA, Almeida AJ, et al. Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease. Arq Bras Cardiol 2006;87:159-66.
89. Chachques JC. Cellular cardiac regenerative therapy in which patients? Expert Rev Cardiovasc Ther 2009;7:911-9.
90. Labovsky V, Smulski CR, Gómez K, Levy G, Levin MJ. Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 2007;148:440-9.
91. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in ′1-adrenoreceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012; Aug 14 [Epub ahead of print].
92. Schimke I, Haberland A, Kage A, Wallukat G, Dahmen C. Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta1-adrenergic receptor. Pub. No.: WO/2012/000889, International Application No.: PCT/EP2011/06057; Publication Date: 05.01.2012, International Filing Date: 23.06.2011.
93. Haberland A, Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011;109:986-92.
94. Wallukat G, Haberland A, Berg S, Schulz A, Freyse EJ, Dahmen C, et al. The fi rst aptamer-apheresis column specifi cally for clearing blood of beta1-receptor autoantibodies: a successful proof of principle using autoantibody positive SHR rats. Circ J 2012;76:2449-55.
95. Wallukat G, Haberland A, Schimke I. Use of aptamers in therapy and/or diagnosis of autoimmune diseases. EP 2 497 828 A1, Application Number: 11157229.3; Date of Publication: 12.09.2012; Date of Filing: 07.03.2011.
96. Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2000;2:258-63.
97. Haberland A, Wallukat G, Schimke I. Aptamer binding and neutralization of b(1)-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment. Trends Cardiovasc Med 2011;21:177-82.
98. Diaz C, Nussenzweig V, Gonzalez A. An improved polymerase chain reaction assay to detect Trypanosoma cruzi in blood. Am J Trop Med Hyg 1992;46:616-23.
99. Vago AR, Macedo AM, Adad SJ, Reis DD, Corrêa-Oliveira R. PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas'disease. Lancet 1996;348:891-2.
100. Schijman AG, Bisio M, Orellana L, Sued M, Duff y T, Mejia Jaramillo AM, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011;5:e931.
101. Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis 2010;10:337.
102. Pinto AY, Valente SA, Valente Vda C, Ferreira Junior AG, Coura JR. Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Pará, Amapáand Maranhão observed between 1988 and 2005. Rev Soc Bras Med Trop 2008;41:602-14.
103. Otani MM, Vinelli E, Kirchhoff LV, del Pozo A, Sands A, Vercauteren G, et al. WHO comparative evaluation of serologic assays for Chagas disease. Transfusion 2009;49:1076-82.
104. FDA. "Guidance for industry: use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in whole blood and blood components intended for transfusion" . Available from: http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ ucm235855.htm. Accessed on 24 September 2012.
105. Campbell DA, Westenberger SJ, Sturm NR. The determinants of Chagas disease: connecting parasite and host genetics. Curr Mol Med 2004;4:549-62.
106. García Borrás S, Racca L, Cotorruelo C, Biondi C, Beloscar J, Racca A. Distribution of HLA-DRB1 alleles in Argentinean patients with Chagas'disease cardiomyopathy. Immunol Invest 2009;38:268-75.
107. Cruz-Robles D, Chávez-González JP, Cavazos-Quero MM, Pérez-Méndez O, Reyes PA, Vargas-Alarcón G. Association between IL-1B and IL-1RN gene polymorphisms and Chagas'disease development susceptibility. Immunol Invest 2009;38:231-9.
108. Ramasawmy R, Fae KC, Cunha-Neto E, Müller NG, Cavalcanti VL, Ferreira RC, et al. Polymorphisms in the gene for lymphotoxinalpha predispose to chronic Chagas cardiomyopathy. J Infect Dis 2007;196:1836-43.
109. Zafra G, Morillo C, Mart ín J, González A, González CI. Polymorphism in the 3'UTR of the IL12B gene is associated with Chagas'disease cardiomyopathy. Microbes Infect 2007;9:1049-52.
110. Ramasawmy R, Cunha-Neto E, Fae KC, Martello FG, Müller NG, Cavalcanti VL, et al. The monocyte chemoattractant protein-1 gene polymorphism is associated with cardiomyopathy in human chagas disease. Clin Infect Dis 2006;43:305-11.
111. Cunha-Neto E, Teixeira PC, Fonseca SG, Bilate AM, Kalil J. Myocardial gene and protein expression profi les aft er autoimmune injury in Chagas'disease cardiomyopathy. Autoimmun Rev 2011;10:163-5.
112. Ndao M, Spithill TW, Caff rey R, Li H, Podust VN, Perichon R, et al. Identifi cation of novel diagnostic serum biomarkers for Chagas'disease in asymptomatic subjects by mass spectrometric profi ling. Clin Microbiol 2010;48:1139-49.
113. Ndao M. Biomarker discovery in serum/plasma using surface enhanced laser desorption ionization time of flight (SELDI-TOF) mass spectrometry. Methods Mol Biol 2012;818:67-79.
114. Mu ñoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, et al. Distinct patterns of autoantibodies against G-protein coupled receptors in Chagas'cardiomyopathy and megacolon: their potential impact for early risk assessment in asymptomatic Chagas'patients. J Am Coll Cardiol 2010;56:526-7.
115. Goin JC, Borda E, Auger R, Storino R, Sterni-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. Heart 1999;82:273-8.
116. Nikolaev VO, Boivin V, Störk S, Angermann CE, Ertl G, Lohse MJ, et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007;50:423-31.
117. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999;99:649-54.
118. Limas CJ, Goldenberg IF, Limas C. Assessment of immune modulation of beta-adrenergic pathways in human dilated cardiomyopathy: influence of methodologic factors. Am Heart J 1992;123:967-70.
119. Del Corsso C, de Carvalho AC, Martino HF, Varanda WA. Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits. Am J Physiol Heart Circ Physiol 2004;287:H1928-36.
120. Aguiar C, Batista AM, Pavan TB, Almeida EA, Guariento ME, Wanderley JS, et al. Serological profi les and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole. Trop Med Int Health 2012;17:368-73.
121. de Freitas VL, da Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, et al. Real-time PCR in HIV/Trypanosoma cruzi coinfection with and without Chagas disease reactivation: association with HIV viral load and CD4 level. PLoS Negl Trop Dis 2011;5:e1277.
122. Talvani A, Teixera MM. Inflammation and Chagas disease: some mechanisms and relevance. Adv Parasitol 2011;76:171-94.
123. Cervetta L, Moretti E, Basso B. Experimental Chagas'disease. The protection induced by immunization with Trypanosoma rangeli is associated with down-regulation of IL-6, TNF-a and IL-10 synthesis. Acta Parasitol 2002;47:73-8.
124. Pakianathan DR, Kuhn RE. Interleukin-2 receptors in experimental Chagas'disease. Infect Immun 1992;60:3904-8.
125. Medrano-Mercado N, Luz MR, Torrico F, Tapia G, Van Leuven F, Araujo-Jorge TC. Acute-phase proteins and serologic profi les of chagasic children from an endemic area in Bolivia. Am J Trop Med Hyg 1996;54:154-61.
126. Medrano NM, Luz MR, Cabello PH, Tapia GT, Van Leuven F, Ara újo-Jorge TC. Acute Chagas'disease: plasma levels of alpha-2- macroglobulin and C-reactive protein in children under 13 years in a high endemic area of Bolivia. J Trop Pediatr 1996;42:68-74.
127. Pascale JM, Sousa CE, Orn A. Evaluation of interleukin-2 soluble receptor in patients with tripanosomiasis Americana in Panama. Rev Med Panama 1991;16:184-8.
128. Pascale JM, Sousa OE, Orn A. Determination of soluble interleukin-2 receptor in patients with American trypanosomiasis in Panama. Rev Med Panama 1992;17:12-6.
129. Moretti E, Basso B, Cervetta L, Brigada A, Barbieri G. Patterns of cytokines and soluble cellular receptors in the sera of children with acute Chagas'disease. Clin Diagn Lab Immunol 2002;9:1324-7.
130. Ramasawmy R, Cunha-Neto E, FaéKC, Müller NG, Cavalcanti VL, Drigo SA, et al. BAT1, a putative anti-inflammatory gene, is associated with chronic Chagas cardiomyopathy. J Infect Dis 2006;93:1394-9.
131. López L, Arai K, Giménez E, Jiménez M, Pascuzo C, Rodríguez-Bonfante C, et al. C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure. Rev Esp Cardiol 2006;59:50-6.
132. Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Reynaga DD, et al. Cardiac troponin T measured with a highly sensitive assay for diagnosis and monitoring of heart injury in chronic Chagas'disease. Arch Pathol Lab Med 2011;135:243-8.
133. Aparecida da Silva C, Fattori A, Sousa AL, Mazon SB, Monte Alegre S, Almeida EA, et al. Determining the C-reactive protein level in patients with diff erent clinical forms of chagas disease. Rev Esp Cardiol 2010;63:1096-9.
134. Cetron MS, Basilio FP, Moraes AP, Sousa AQ, Paes JN, Kahn SJ, et al. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas'disease patients with symptomatic versus indeterminate infection. Am J Trop Med Hyg 1993;49:370-82.
135. Melo LM, Souza GE, Valim LR, Moreira LF, Damico EA, Rocha TR, et al. Study of pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq Bras Cardiol 2010;95:655-62.
136. Mocelin AO, Issa VS, Bacal F, Guimarães GV, Cunha E, Bocchi EA. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas'heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005;7:869-73.
137. Ferreira RC, Ianni BM, Abel LC, Buck P, Mady C, Kalil J, et al. Increased plasma levels of tumor necrosis factor-alpha in asymp tomatic/ "indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz 2003;98:407-11.
138. Lula JF, Rocha MO, Nunes Mdo C, Ribeiro AL, Teixeira MM, Bahia MT, et al. Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosisinducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction. Eur J Heart Fail 2009;11:825-31.
139. Pérez-Fuentes R, López-Colombo A, Ord óñez- Toquero G, Gomez-Albino I, Ramos J, Torres-Rasgado E, et al. Correlation of the serum concentrations of tumour necrosis factor and nitric oxide with disease severity in chronic Chagas disease (American trypanosomiasis). Ann Trop Med Parasitol 2007;101:123-32.
140. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis 2004;38:943-50.
141. Rodrigues DB, Correia D, Marra MD, Giraldo LE, Lages-Silva E, Silva-Vergara ML, et al. Cytokine serum levels in patients infected by human immunodefi ciency virus with and without Trypanosoma cruzi coinfection. Rev Soc Bras Med Trop 2005;38:483-7.
142. Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, et al. Cytokine levels in serious cardiopathy of Chagas disease aft er in vitro stimulation with recombinant antigens from Trypanosoma cruzi. Scand J Immunol 2010;72:529-39.
143. de Melo AS, de Lorena VM, de Moura Braz SC, Docena C, de Miranda Gomes Y. IL-10 and IFN-g gene expression in chronic Chagas disease patients aft er in vitro stimulation with recombinant antigens of Trypanosoma cruzi. Cytokine 2012;58: 207-12.
144. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specifi c immune responses aft er treatment: surrogate markers of treatment effi cacy. Clin Infect Dis 2009;49:1675-84.
145. Piacenza L, Alvarez MN, Peluff o G, Radi R. Fighting the oxidative assault: the Trypanosoma cruzi journey to infection. Curr Opin Microbiol 2009;12:415-21.
146. Wen JJ, Dhiman M, Whorton EB, Garg NJ. Tissue-specifi c oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice. Microbes Infect 2008;10:1201-9.
147. Báez AL, Lo Presti MS, Rivarola HW, Pons P, Fretes R, Paglini-Oliva P. Trypanosoma cruzi: cardiac mitochondrial alterations produced by diff erent strains in the acute phase of the infection. Exp Parasitol 2008;120:397-402.
148. Ribeiro CM, Budni P, Pedrosa RC, Farias MS, Parisotto EB, Dalmarco EM, et al. Antioxidant therapy attenuates oxidative insult caused by benzonidazole in chronic Chagas'heart disease. Int J Cardiol 2010;145:27-33.
149. Wen JJ, Bhatia V, Popov VL, Garg NJ. Phenyl-alpha-tert-butyl nitrone reverses mitochondrial decay in acute Chagas'disease. Am J Pathol 2006;169:1953-64.
150. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500-8.
151. de Oliveira TB, Pedrosa RC, Filho DW. Oxidative stress in chronic cardiopathy associated with Chagas'disease. Int J Cardiol 2007;116:357-63.
152. Gupta S, Dhiman M, Wen JJ, Garg NJ. ROS signalling of inflammatory cytokines during Trypanosoma cruzi infection. Adv Parasitol 2011;76:153-70.
153. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-23.
154. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R, Giustarini D. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 2009;46:241-81.
155. Maçao LB, Wilhelm Filho D, Pedrosa RC, Pereira A, Backes P, Torres MA, et al. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas'disease. Int J Cardiol 2007;123:43-9.
156. Palhares PE, Marcondes NS, Fontana Júnior P, Schaeff er GM, Bastos OM. Correlation between tissue damage and malondialdehydemia in mice infected with Trypanosoma cruzi. Braz J Med Biol Res 1987;20:795-8.
157. Palhares PE, Marcondes NS, Fontana Júnior P, Schaeff er GM, Bastos OM. Malondialdehydemia and parasitemia during acute phase of experimental Chagas'disease in mice. Braz J Med Biol Res 1987;20:799-801.
158. Palhares PE, Fontana Júnior P, Schaff er GM, Marcondes NS, Vergara M. Tissue damage markers in experimental Chagas'disease. Braz J Med Biol Res 1988;21:957-9.
159. Wen JJ, Vyatkina G, Garg N. Oxidative damage during chagasic cardiomyopathy development: role of mitochondrial oxidant release and ineffi cient antioxidant defense. Free Radic Biol Med 2004;37:1821-33.
160. Michowitz Y, Kisil S, Guzner-Gur H, Rubinstein A, Wexler D, Sheps D, et al. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr Med Assoc J 2008;10:884-8.
161. Dhiman M, Estrada-Franco JG, Pando JM, Ramirez-Aguilar FJ, Spratt H, Vazquez-Corzo S, et al. Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas'disease. Clin Vaccine Immunol 2009;16:660-6.
162. Munoz Saravia SG. Chronische Chagas-Erkrankung. Dissertation 2010, Berlin. Available from: http://www.diss.fu-berlin. de/diss/receive/FUDISS- thesis-000000015711. Accessed on 24 September 2012.
163. Wen JJ, Yachelini PC, Sembaj A, Manzur RE, Garg NJ. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radic Biol Med 2006;41:270-6.
164. Pérez-Fuentes R, Guégan JF, BarnabéC,
165. Pérez-Fuentes R, Torres-Rasgado E, Salgado-Rosas H, Zamora-Ginez I, Sánchez-Guillén MC. The anti-oxidant defence response in individuals with the indeterminate form of Chagas disease (American trypanosomiasis). Ann Trop Med Parasitol 2008;102:189-97.
166. Rivera MT, de Souza AP, Moreno AH, Xavier SS, Gomes JA, Rocha MO, et al. Progressive Chagas'cardiomyopathy is associated with low selenium levels. Am J Trop Med Hyg 2002;66:706-12.
167. Piacenza L, Zago MP, Peluff o G, Alvarez MN, Basombrio MA, Radi R. Enzymes of the antioxidant network as novel determiners of Trypanosoma cruzi virulence. Int J Parasitol 2009;39:1455-64.
168. Díaz ML, Solari A, González CI. Diff erential expression of Trypanosoma cruzi I associated with clinical forms of Chagas disease: overexpression of oxidative stress proteins in acute patient isolate. J Proteomics 2011;74:1673-82.
169. Yacoub S, Birks EJ, Slavik Z, Henein M. Early detection of myocardial dysfunction in Chagas disease using novel echocardiographic indices. Trans R Soc Trop Med Hyg 2003;97: 528-34.
170. Dubner S, Schapachnik E, Riera AR, Valero E. Chagas disease: state-of-the-art of diagnosis and management. Cardiol J 2008;15:493-504.
171. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. J Am Med Assoc 2007;298:2171-81.
172. Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 2004;90:655-60.
173. Acuatella H. Echocardiography in Chagas heart disease. Circulation 2007;115:1124-31.
174. Shehata ML, Turkbey EB, Vogel-Claussen J, Bluemke DA. Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies. Top Magn Reson Imaging 2008;19:43-57.
175. Tanowitz HB, Machado FS, Jelicks LA, Shirani J, de Carvalho AC, Spray DC, et al. Perspectives on Trypanosoma cruziinduced heart disease (Chagas disease). Prog Cardiovasc Dis 2009;51:524-39.
176. Carrasco HA, Alarcon M, Olmos L, Burguera J, Burguera M, Dipaolo A, et al. Biochemical characterization of myocardial damage in chronic Chagas'disease. Clin Cardiol 1997;20:865-9.
177. Alarcón-Corredor OM, Carrasco-Guerra H, Ramírez de Fernández M, León W. Serum enzyme pattern and local enzyme gradients in chronic chagasic patients. Acta Cient Venez 2002;53:210-7.
178. Shen W, Spindler M, Higgins MA, Jin N, Gill RM, Bloem LJ, et al. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J Mol Cell Cardiol 2005;39:537-44.
179. Teixeira PC, Santos RH, Fiorelli AI, Bilate AM, Benvenuti LA, Stolf NA, et al. Selective decrease of components of the creatine kinase system and ATP synthase complex in chronic Chagas disease cardiomyopathy. PLoS Negl Trop Dis 2011;5: e1205.
180. Sturk A, Sanders GT. Macro enzymes: prevalence, composition, detection and clinical relevance. J Clin Chem Clin Biochem 1990;28:65-81.
181. Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
182. Piazza LA, de Bold AJ, Santamarina N, Hliba E, Rubiolo ER. Atrial natriuretic factor in experimental acute Chagas'disease. Parasitol Res 1994;80:78-80.
183. Puyó AM, Scaglione J, Auger S, Cavallero S, Donoso AS, Dupuy HA, et al. Atrial natriuretic factor as marker of myocardial compromise in Chagas'disease. Regul Pept 2002;105:139-43.
184. Ribeiro AL, dos Reis AM, Barros MV, de Sousa MR, Rocha AL, Perez AA, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas'disease. Lancet 2002;360:461-2.
185. Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos J, Ribeiro AL, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz 2004;99:645-9.
186. Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos J, Ribeiro AL, et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int J Cardiol 2005;100:503-4.
187. Melo RB, Parente GB, Victor EG. Measurement of human brain natriuretic peptide in patients with Chagas disease. Arq Bras Cardiol 2005;84:137-40.
188. Vilas-Boas F, Feitosa GS, Soares MB, Pinho-Filho JA, Nascimento T, Barojas MM, et al. Invasive and noninvasive correlations of B-type natriuretic peptide in patients with heart failure due to Chagas cardiomyopathy. Congest Heart Fail 2008;4:121-6.
189. Marques DS, Canesin MF, Barutta Júnior F, Fuganti CJ, Barretto AC. Evaluation of asymptomatic patients with chronic Chagas disease through ambulatory electrocardiogram, echocardiogram and B-Type natriuretic peptide analyses. Arq Bras Cardiol 2006;87:336-43.
190. Heringer-Walther S, Moreira MC, Wessel N, Saliba JL, Silvia-Barra J, Pena JL, et al. Brain natriuretic peptide predicts survival in Chagas'disease more eff ectively than atrial natriuretic peptide. Heart 2005;91:385-7.
191. Moreira Mda C, Heringer-Walther S, Wessel N, Moreira Ventura T, Wang Y, Schultheiss HP, et al. Prognostic value of natriuretic peptides in Chagas'disease: a 3-year follow-up investigation. Cardiology 2008;110:217-5.
192. Ribeiro AL, Teixeira MM, Reis AM, Talvani A, Perez AA, Barros MV, et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol 2006;109:34-40.
193. Sousa L, Botoni FA, Britto RR, Rocha MO, Teixeira AL Jr, Teixeira MM, et al. Six-minute walk test in Chagas cardiomyopathy. Int J Cardiol 2008;125:139-41.
194. Lima MM, Nunes MC, Rocha MO, Beloti FR, Alencar MC, Ribeiro AL. Left ventricular diastolic function and exercise capacity in patients with Chagas cardiomyopathy. Echocardiography 2010;27:519-24.
195. Oliveira BM, Botoni FA, Ribeiro AL, Pinto AS, Reis AM, Nunes Mdo C, et al. Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle fi lling pressure in patients with Chagasic cardiomyopathy. Echocardiography 2009;26:521-7.
196. Garcia-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identifi cation of cardiac damage. PLoS Negl Trop Dis 2010;4. pii:e826.
197. Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in communitydwelling older adults with Chagas disease: 10-year followup of the Bambui Cohort Study of Aging. Am J Epidemiol 2010;172:190-6.
198. Fernandes F, Dantas S, Ianni BM, Ramires FJ, Buck P, Salemi VM, et al. Leptin levels in diff erent forms of Chagas'disease. Braz J Med Biol Res 2007;40:1631-6.
199. Barbosa MM, Nunes Mdo C, Ribeiro AL, Barral MM, Rocha MO. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur J Echocardiogr 2007;8:204-12.
200. Mady C, Fernandes F, Arteaga E, Ramires FJ, Buck Pde C, Salemi VM, et al. Serum NT pro-BNP: relation to systolic and diastolic function in cardiomyopathies and pericardiopathies. ArQ Bras Cardiol 2008;91:46-50.
201. Scirica BM, Morrow DA. Troponins in acute coronary syndromes. Prog Cardiovasc Dis 2004;47:177-88.
202. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
203. Jaffe AS. Elevation in cardiac troponin measurements: false false-positives. Cardiovasc Toxicol 2001;1:87-92.
204. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142:786-91.
205. Schulz O, Kirpal K, Stein J, Bensch R, Berghöfer G, Schimke I, et al. Importance of low concentrations of cardiac troponins. Clin Chem 2006;52:1614-5.
206. Saravia SG, Knebel F, Schroeckh S, Ziebig R, Lun A, Weimann A, et al. Cardiac troponin T release and inflammation demonstrated in marathon runners. Clin Lab 2010;56:51-8.
207. Basquiera AL, Capra R, Omelianiuk M, Amuchástegui M, Madoery RJ, Salomone OA. Serum troponin T in patients with chronic Chagas disease. Rev Esp Cardiol 2003;56:742-4.
208. Arias R, Bastos C, Mota G, Sodré F, Moreira A, Tavares A, et al. Troponin in Chagas disease. Braz J Infect Dis 2003;7:358-9.
209. Machado MN, Suzuki FA, Mouco OC, Hernandes ME, Lemos MA, Maia LN. Positive troponin T in a chagasic patient with sustained ventricular tachycardia and no obstructive lesions on cine coronary angiography. Arq Bras Cardiol 2005;84: 182-4.
210. Mu ñoz-Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas'heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev 2012;17:45-64.